Hemax

Hemax

epoetin alfa

Manufacturer:

Bio Sidus

Distributor:

BJC Healthcare
Concise Prescribing Info
Contents
r-Hu-erythropoietin α (epoetin α)
Indications/Uses
Anemia caused by chronic renal failure; anemia in HIV-infected patients (zidovudine-induced); anemia in cancer patients on chemotherapy; reduction of allogeneic blood transfusion in anemic patients who undergo elective surgery; anemia in premature infants.
Dosage/Direction for Use
Initial dose: Anemia in chronic renal failure patients Adult 50-100 IU/kg 3x a wk IV or SC. Childn weighing >30 kg 30-100 IU/kg 3x wkly, 10-30 kg 60-150 IU/kg 3x wkly, <10 kg 75-150 IU/kg 3x wkly. Initial dose is same as adult dose. Anemia in HIV-infected patients (zidovudine-induced) 100 IU/kg 3x wkly IV or SC for 8 wk. Anemia in cancer patients on chemotherapy Adult 150 IU/kg/dose 3x a wk SC, may be increased by 50 U/kg/dose each time. Max: 300 U/kg 3x wkly or initially 40,000 IU SC once wkly. TIW administration: If Hb level reaches 12 g/dL or increases >1 g/dL w/in 2 wk, reduce dose by 25%. If hematocrit is 40%, interrupt therapy until value reaches 36%. Reduce dose by 25% when treatment is re-initiated. Single wkly administration: Increase to 60,000 IU if Hb did not increase 1 g/dL in 4 wk. If Hemax triggers rapid response, reduce dose by 25%. Childn 6 mth to 18 yr 25-300 IU/kg IV or SC 3-7x wkly. Reduction of allogeneic blood transfusion in surgery patients 150-300 IU/kg/day SC starting 10 days before surgery & continuing up to 4 days after. Alternatively, 600 IU/kg. SC unique wkly doses on days 21, 14, & 7 prior to surgery & 4th dose on surgery day. Anemia of prematurity 250 IU/kg 3x a wk SC.
Contraindications
Hypersensitivity to human albumin & products derived from mammalian cells. Uncontrolled arterial HTN, epoetin-related pure red cell aplasia.
Special Precautions
History of porphyria. Evaluate if patients fail to respond or maintain response: Fe deficiency, underlying infections or inflammatory processes or neoplasia, occult blood loss, underlying haematologic disease (thalasaemia, myelodysplasia), haemolysis, Al overload, vit deficiencies (vit B12 or folic acid), cystic fibrosis, pure red cell aplasia, bone marrow fibrosis & suppression from uremia, hyperparathyroidism/osteitis fibrosa cystica, erythrocyte enzyme abnormalities. K level may increase w/ large food intake. Pregnancy & lactation.
Adverse Reactions
Arterial HTN, headaches, oedema, low back pain, polycythemia, thrombotic complication, fever, hyperkalemia, breathing difficulties, tachycardia, seizures, arthralgias; oedema, fever; urticaria; DVT, UTI.
MIMS Class
Haematopoietic Agents / Supportive Care Therapy
ATC Classification
B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Presentation/Packing
Form
Hemax powd for inj 1,000 IU
Packing/Price
1's;25 × 1's
Form
Hemax powd for inj 10,000 IU
Packing/Price
1's;25 × 1's
Form
Hemax powd for inj 2,000 IU
Packing/Price
1's;25 × 1's
Form
Hemax powd for inj 3,000 IU
Packing/Price
1's;25 × 1's
Form
Hemax powd for inj 4,000 IU
Packing/Price
1's;25 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in